Effect of Sequential or Active Choice for Colorectal Cancer Screening Outreach: A Randomized Clinical Trial.
Academic Medical Centers
/ organization & administration
Aged
Choice Behavior
/ physiology
Colonoscopy
/ standards
Colorectal Neoplasms
/ diagnosis
Economics, Behavioral
Female
Humans
Intention to Treat Analysis
/ statistics & numerical data
Male
Mass Screening
/ methods
Middle Aged
Occult Blood
Philadelphia
/ epidemiology
Postal Service
/ methods
Primary Health Care
/ standards
Prospective Studies
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
02 08 2019
02 08 2019
Historique:
entrez:
31
8
2019
pubmed:
31
8
2019
medline:
17
6
2020
Statut:
epublish
Résumé
Colonoscopy and fecal immunochemical testing (FIT) are considered top-tier tests for colorectal cancer (CRC) screening. Behavioral economic insights about "choice architecture" suggest that participation could be influenced by how people are presented test options. To investigate response rates for offering colonoscopy only compared with sequential choice (colonoscopy and then FIT) or active choice (colonoscopy or FIT) through mailed outreach. Three-arm pragmatic randomized clinical trial conducted between November 14, 2017, and May 14, 2018. The setting was primary care practices at an academic health system. Patients aged 50 to 74 years with at least 2 primary care visits in the 2-year preenrollment period were included if they were eligible but not up to date on CRC screening. Eligible patients received mailed outreach about CRC screening. Equal numbers of eligible patients were randomly assigned to 3 outreach groups to receive mailings about CRC screening with the following options: (1) direct phone number to call for scheduling colonoscopy (colonoscopy only), (2) direct phone number to call for colonoscopy and a mailed FIT kit if no response within 4 weeks (sequential choice), or (3) direct phone number to call for colonoscopy and a mailed FIT kit offered at the same time (active choice). The primary outcome was CRC screening completion (FIT or colonoscopy) within 4 months of initial outreach. The secondary outcomes were CRC screening completion within 6 months of outreach and the choice of colonoscopy as a screening test. In total, 438 patients were included in the intent-to-treat analysis, with a median age of 56 years (interquartile range, 52-63 years); 55.0% were women. At 4 months, the CRC screening completion rates were 14.4% (95% CI, 8.7%-20.1%) in the colonoscopy-only arm, 17.1% (95% CI, 11.0%-23.2%) in the sequential choice arm, and 19.9% (95% CI, 13.4%-26.4%) in the active choice arm. Neither choice arm achieved a screening rate statistically greater than that in the colonoscopy-alone arm. Among those who completed CRC screening at 4 months, 90.5% (95% CI, 78.0%-103.0%) chose colonoscopy in the colonoscopy-only arm, which was significantly higher than the 52.0% (95% CI, 32.4%-71.6%; P = .005) and 37.9% (95% CI, 20.2%-55.6%; P < .001) in the sequential choice and active choice arms, respectively. There was no significant increase in CRC screening when offering sequential or active choice, but there was a lower rate of colonoscopy in the choice arms than in the colonoscopy-only arm. Subtle changes in sequencing or defaults can alter patient decision making related to preventive health. ClinicalTrials.gov identifier: NCT03246438.
Identifiants
pubmed: 31469393
pii: 2749265
doi: 10.1001/jamanetworkopen.2019.10305
pmc: PMC6724166
doi:
Banques de données
ClinicalTrials.gov
['NCT03246438']
Types de publication
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1910305Subventions
Organisme : NCI NIH HHS
ID : K08 CA234326
Pays : United States
Organisme : NIDDK NIH HHS
ID : R25 DK108711
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG034546
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213645
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
J Pers Soc Psychol. 2000 Dec;79(6):995-1006
pubmed: 11138768
Science. 2003 Nov 21;302(5649):1338-9
pubmed: 14631022
Sci Am. 2004 Apr;290(4):70-5
pubmed: 15045756
J Natl Cancer Inst. 2005 Mar 2;97(5):347-57
pubmed: 15741571
Med J Aust. 2006 Jun 5;184(11):546-50
pubmed: 16768659
Obstet Gynecol. 2007 Jul;110(1):81-6
pubmed: 17601900
Cancer. 2007 Nov 1;110(9):2083-91
pubmed: 17893869
N Engl J Med. 2007 Sep 27;357(13):1340-4
pubmed: 17898105
JAMA. 2007 Nov 28;298(20):2415-7
pubmed: 18042920
J Pers Soc Psychol. 2008 May;94(5):883-98
pubmed: 18444745
JAMA. 2010 Jul 7;304(1):43-4
pubmed: 20606147
Gut. 2013 May;62(5):735-40
pubmed: 22442162
Arch Intern Med. 2012 Apr 9;172(7):575-82
pubmed: 22493463
N Engl J Med. 2012 Jun 21;366(25):2345-57
pubmed: 22612596
Ann Intern Med. 2013 Mar 5;158(5 Pt 1):301-11
pubmed: 23460053
JAMA Intern Med. 2013 Oct 14;173(18):1725-32
pubmed: 23921906
Clin Gastroenterol Hepatol. 2014 May;12(5):711-4
pubmed: 24746170
Am J Gastroenterol. 2016 Jan;111(1):105-14
pubmed: 26526080
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
J Gen Intern Med. 2016 Nov;31(11):1323-1330
pubmed: 27412426
Gut. 2018 Feb;67(2):291-298
pubmed: 27733426
MMWR Morb Mortal Wkly Rep. 2017 Mar 03;66(8):201-206
pubmed: 28253225
Am J Gastroenterol. 2017 Jul;112(7):1016-1030
pubmed: 28555630
Gastroenterology. 2017 Nov;153(5):1227-1229.e2
pubmed: 28734830
N Engl J Med. 2017 Oct 12;377(15):1412-1414
pubmed: 29020586
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
CA Cancer J Clin. 2018 Jul;68(4):250-281
pubmed: 29846947
Am J Gastroenterol. 2018 Dec;113(12):1848-1854
pubmed: 29925915
JAMA Intern Med. 2018 Dec 1;178(12):1645-1658
pubmed: 30326005
JAMA Netw Open. 2019 Mar 1;2(3):e191156
pubmed: 30901053
Science. 1981 Jan 30;211(4481):453-8
pubmed: 7455683
N Engl J Med. 1993 May 13;328(19):1365-71
pubmed: 8474513